CRI market research report

Human Genetics Market—Forecast till 2027

$4950 – $7250

The global human genetics market is anticipated to register a substantial market expansion at a notable CAGR of 17.76% during the review period to surpass USD 1,12,536.54 million by 2027.

SKU: MRFR220284 Category: Tag:

Description

Human Genetics Market—Forecast till 2027

Market Snapshot

The global human genetics market is anticipated to register a substantial market expansion at a notable CAGR of 17.76% during the review period to surpass USD 1,12,536.54 million by 2027.Human genetics is the investigation of the conveyance of qualities through ages. Adjustment in the genome might bring about change, a little piece of which might prompt the infection aggregate.

Hereditary sicknesses can be monogenic, multifactorial, and chromosomal are passed down from the guardians to the descendants by various legacy designs, for example, X-connected latent, autosomal passive, and autosomal prevailing. Developing predominance of epilepsy among the geriatric populace go about as significant driver in the worldwide human genetics market during 2021-2027.

Nonetheless, significant expense of hereditary testing impedes the development of the worldwide human genetics market during the conjecture time frame. The developing utilization of hereditary information across medical services and innovative progression in hereditary testing is relied upon to set out a freedom in the worldwide human genetics market.

Market Segmentation

Global Human Genetics Market has been segregated based on Application, and test.Based on application the global market has been classified into Wellness & E-Commerce, Preventive Medicine, Diagnostic & Treatment, Oncology, Cardiology, Assisted Reproduction, Neurology, Gynaecology, and others.The neurology segment is further sub-divided into Neuropediatric and Others. Based on the Test segment, the Global Human Genetics Market has been categorized into NIPT, Carrier Testing, Pharmacogenomic Testing, Thrombophilia Testing, Septin 9 Biomarker Testing, NGS, and others.

Regional Analysis

Geographically, the global human genetics market, has been studied across the US, Canada, UK, Germany, Spain, Japan, Others.The human genetics market in the US benefits from a high medical care use, expanding interest for hereditary testing by the populace, and high open mindfulness with respect to early discovery of infections and preventive consideration.

Also, the accessibility of repayments in the US for hereditary tests further develops market development in the country. Genomic wellbeing information in the UK is created in three significant regions, including enormous scope research programs, the medical services framework, and buying of direct-to-purchaser hereditary testing. Additionally, the ascent in the number of drives embraced by people in general as well as private associations is further supporting the market development.

In Germany, the rising commonness of hereditary issues, disease, expanding mindfulness and acknowledgment regarding customized meds, and developing spotlight on R&D exercises add to the nation’s development. Also, the public authority is executing various good and cooperative approaches to consolidate hereditary testing into the medical care framework and give protection repayments to residents, which, thusly, is driving the market development.DNA testing at home in Japan is acquiring a foothold among the older populace looking for answers in regard to their wellbeing and illness chances.

Major Players

The Key Companies operating in the global human genetics market includes GENinCode (UK), Atrys Health (Spain), Genyca (Spain), Igenomix (India), Genologica (Spain), Myriad Genetics (US), NIMGenetics (Spain), Sistemas Genómicos (Spain), FullGenomics (Spain), Synlab Group (Germany), Eurofins Megalab S.A (Spain), Biomarker Technology (US), Echevarne Laboratory (Spain), Elabscience Biotechnology Inc (US), and Bode Technology Group Inc (US).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENTS 1 EXECUTIVE SUMMARY 14 2 MARKET INTRODUCTION 15 2.1 DEFINITION 15 2.2 SCOPE OF THE STUDY 15 2.3 RESEARCH OBJECTIVE 15 2.4 MARKET STRUCTURE 15 2.5 ASSUMPTIONS & LIMITATIONS 16 3 RESEARCH METHODOLOGY 17 3.1 DATA MINING 17 3.2 SECONDARY RESEARCH 18 3.3 PRIMARY RESEARCH 19 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 20 3.5 FORECASTING TECHNIQUES 21 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22 3.6.1 BOTTOM-UP APPROACH 23 3.6.2 TOP-DOWN APPROACH 23 3.7 DATA TRIANGULATION 24 3.8 VALIDATION 24 4 MARKET DYNAMICS 25 4.1 OVERVIEW 25 4.2 DRIVERS 26 4.2.1 GROWING ADOPTION OF GENETIC TESTING 26 4.2.2 INCREASING INCIDENCES OF GENETIC DISEASES AND CANCER 26 4.3 RESTRAINTS 27 4.3.1 HIGH COST OF GENETIC TESTING 27 4.3.2 SHORTAGE OF SKILLED AND EXPERIENCED GENETIC COUNSELORS 27 4.4 OPPORTUNITY 28 4.4.1 GROWING USE OF GENETIC DATA ACROSS HEALTHCARE AND TECHNOLOGICAL ADVANCEMENTS IN GENETIC TESTING 28 5 MARKET FACTOR ANALYSIS 29 5.1 VALUE CHAIN ANALYSIS 29 5.1.1 R&D 30 5.1.2 MANUFACTURING 30 5.1.3 DISTRIBUTION & SALES 30 5.1.4 POST-SALES MONITORING 30 5.2 PORTER'S FIVE FORCES MODEL 31 5.2.1 THREAT OF NEW ENTRANTS 31 5.2.2 BARGAINING POWER OF SUPPLIERS 32 5.2.3 THREAT OF SUBSTITUTES 32 5.2.4 BARGAINING POWER OF BUYERS 32 5.2.5 INTENSITY OF RIVALRY 32 5.3 IMPACT OF COVID-19 ON THE GLOBAL HUMAN GENETICS MARKET 32 5.3.1 IMPACT ON SUPPLY CHAIN 32 5.3.2 IMPACT ON PATIENTS SUFFERING FROM GENETIC DISEASES 33 5.3.3 IMPACT ON KEY PLAYERS 33 6 GLOBAL HUMAN GENETICS MARKET, BY APPLICATION 34 6.1 OVERVIEW 34 6.2 WELLNESS & E-COMMERCE 35 6.3 PREVENTIVE MEDICINE 35 6.4 DIAGNOSTIC & TREATMENT 36 7 GLOBAL HUMAN GENETICS MARKET, BY TEST 42 7.1 OVERVIEW 42 7.2 NIPT 43 7.3 CARRIER TESTING 44 7.4 PHARMACOGENOMIC TESTING 45 7.5 KARYOTYPE TESTING 46 7.6 THROMBOPHILIA TESTING 47 7.7 SEPTIN 9 BIOMARKER TESTING 48 7.8 NGS 49 7.9 OTHERS 51 8 GLOBAL HUMAN GENETICS MARKET, BY COUNTRY 52 8.1 OVERVIEW 52 8.1.1 US 53 8.1.2 CANADA 55 8.1.3 UK 57 8.1.4 GERMANY 59 8.1.5 SPAIN 61 8.1.6 JAPAN 63 8.1.7 OTHERS 65 9 COMPETITIVE LANDSCAPE 67 9.1 OVERVIEW 67 9.2 COMPETITIVE BENCHMARKING 68 9.3 MAJOR GROWTH STRATEGY IN THE HUMAN GENETICS MARKET 69 9.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE HUMAN GENETICS MARKET 70 9.5 KEY DEVELOPMENT ANALYSIS 71 9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 71 9.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL 71 9.6.2 MERGER &ACQUISITION 71 9.6.3 EXPANSION 72 9.7 FINANCIAL MATRIX 72 9.7.1 SALES (USD MILLION), 2020 72 10 COMPANY PROFILES 73 10.1 MYRIAD GENETICS, INC. 73 10.1.1 COMPANY OVERVIEW 73 10.1.2 FINANCIAL OVERVIEW 74 10.1.3 PRODUCT/SERVICE OFFERED 75 10.1.4 KEY DEVELOPMENTS 75 10.1.5 SWOT ANALYSIS 76 10.1.6 KEY STRATEGIES 76 10.2 SYNLAB GROUP 77 10.2.1 COMPANY OVERVIEW 77 10.2.2 FINANCIAL OVERVIEW 77 10.2.3 PRODUCT/SERVICE OFFERED 78 10.2.4 KEY DEVELOPMENTS 78 10.2.5 SWOT ANALYSIS 79 10.2.6 KEY STRATEGIES 79 10.3 EUROFINS MEGALAB S.A. 80 10.3.1 COMPANY OVERVIEWS 80 10.3.2 FINANCIAL OVERVIEW 80 10.3.3 PRODUCT/SERVICE OFFERED 81 10.3.4 KEY DEVELOPMENTS 81 10.3.5 SWOT ANALYSIS 81 10.3.6 KEY STRATEGIES 82 10.4 BIOMARKER TECHNOLOGIES. 83 10.4.1 COMPANY OVERVIEW 83 10.4.2 FINANCIAL OVERVIEW 83 10.4.3 PRODUCT/SERVICE OFFERED 83 10.4.4 KEY DEVELOPMENTS 83 10.4.5 SWOT ANALYSIS 84 10.4.6 KEY STRATEGIES 84 10.5 ECHEVARNE LABORATORY 85 10.5.1 COMPANY OVERVIEW 85 10.5.2 FINANCIAL OVERVIEW 85 10.5.3 PRODUCT/SERVICE OFFERED 85 10.5.4 KEY DEVELOPMENTS 85 10.5.5 SWOT ANALYSIS 86 10.5.6 KEY STRATEGIES 86 10.6 ELABSCIENCE BIOTECHNOLOGY INC. 87 10.6.1 COMPANY OVERVIEW 87 10.6.2 FINANCIAL OVERVIEW 87 10.6.3 PRODUCT/SERVICE OFFERED 87 10.6.4 KEY DEVELOPMENTS 87 10.6.5 SWOT ANALYSIS 88 10.6.6 KEY STRATEGIES 88 10.7 NIMGENETICS 89 10.7.1 COMPANY OVERVIEW 89 10.7.2 FINANCIAL OVERVIEW 89 10.7.3 PRODUCT/SERVICE OFFERED 89 10.7.4 KEY DEVELOPMENTS 90 10.7.5 SWOT ANALYSIS 90 10.7.6 KEY STRATEGIES 90 10.8 SISTEMAS GENÓMICOS 91 10.8.1 COMPANY OVERVIEW 91 10.8.2 FINANCIAL OVERVIEW 91 10.8.3 PRODUCTS/SERVICES OFFERED 91 10.8.4 KEY DEVELOPMENTS 91 10.8.5 SWOT ANALYSIS 92 10.8.6 KEY STRATEGIES 92 10.9 FULLGENOMICS 93 10.9.1 COMPANY OVERVIEW 93 10.9.2 FINANCIAL OVERVIEW 93 10.9.3 PRODUCTS/SERVICES OFFERED 93 10.9.4 KEY DEVELOPMENTS 93 10.9.5 SWOT ANALYSIS 94 10.9.6 KEY STRATEGIES 94 10.10 GENINCODE 95 10.10.1 COMPANY OVERVIEW 95 10.10.2 FINANCIAL OVERVIEW 95 10.10.3 PRODUCTS/SERVICES OFFERED 95 10.10.4 KEY DEVELOPMENTS 95 10.10.5 SWOT ANALYSIS 96 10.10.6 KEY STRATEGIES 96 10.11 ATRYS HEALTH 97 10.11.1 COMPANY OVERVIEW 97 10.11.2 FINANCIAL OVERVIEW 97 10.11.3 PRODUCTS/SERVICES OFFERED 97 10.11.4 KEY DEVELOPMENTS 97 10.11.5 SWOT ANALYSIS 98 10.11.6 KEY STRATEGIES 98 10.12 GENYCA 99 10.12.1 COMPANY OVERVIEW 99 10.12.2 FINANCIAL OVERVIEW 99 10.12.3 PRODUCTS/SERVICES OFFERED 99 10.12.4 KEY DEVELOPMENTS 99 10.12.5 SWOT ANALYSIS 100 10.12.6 KEY STRATEGIES 100 10.13 IGENOMIX 101 10.13.1 COMPANY OVERVIEW 101 10.13.2 FINANCIAL OVERVIEW 101 10.13.3 PRODUCTS/SERVICES OFFERED 101 10.13.4 KEY DEVELOPMENTS 101 10.13.5 SWOT ANALYSIS 102 10.13.6 KEY STRATEGIES 102 10.14 GENOLÓGICA 103 10.14.1 COMPANY OVERVIEW 103 10.14.2 FINANCIAL OVERVIEW 103 10.14.3 PRODUCTS/SERVICES OFFERED 103 10.14.4 KEY DEVELOPMENTS 103 10.14.5 SWOT ANALYSIS 104 10.14.6 KEY STRATEGIES 104 10.15 BODE CELLMARK FORENSICS, INC. 105 10.15.1 COMPANY OVERVIEW 105 10.15.2 FINANCIAL OVERVIEW 105 10.15.3 PRODUCTS/SERVICES OFFERED 105 10.15.4 KEY DEVELOPMENTS 105 10.15.5 SWOT ANALYSIS 106 10.15.6 KEY STRATEGIES 106 11 APPENDIX 107 11.1 REFERENCES 107 11.2 RELATED REPORTS 107

Companies Mentioned

GENinCode (UK), Atrys Health (Spain), Genyca (Spain), Igenomix (India), Genologica (Spain), Myriad Genetics (US), NIMGenetics (Spain), Sistemas Genómicos (Spain), FullGenomics (Spain),  Synlab Group (Germany), Eurofins Megalab S.A (Spain), Biomarker Technology (US), Echevarne Laboratory (Spain), Elabscience Biotechnology Inc (US), and Bode Technology Group Inc (US)

Reviews

There are no reviews yet.

Be the first to review “Human Genetics Market—Forecast till 2027”

Related products